Fig 2.

(A) Treatment of phosphoinositide 3–kinase–Akt–mammalian target of rapamycin (PAM) pathway inhibitor–induced hypertriglyceridemia. (*) Therapeutic lifestyle changes (TLC), if appropriate: weight reduction, physical activity, avoid simple sugars (Table 2) and alcohol, consult registered dietician. (†) For triglyceride levels of 150 to 499 mg/dL, triglyceride lowering is secondary to achieving individual LDL cholesterol target. (‡) High risk defined as those continuing to receive PAM pathway inhibitor agent, with anticipated increase in triglycerides, or those with diabetes or cardiovascular (CV) disease (Table 2). (§) Options: fibrates (fenofibrate or gemfibrozil), fish oil (omega-3-ethyl esters), extended-release nicotinic acid. (B) Treatment of PAM pathway inhibitor–induced hypercholesterolemia, if prognosis > 1 year. (*) CV risk equivalents defined in Table 2. (†) TLC in diet and exercise (Table 2).